MindMed Launches Psychedelic-Based Pain Treatment Project

Mind Medicine Inc. (NEO: MMED), also known as MindMed, announced today that it has launched Project Angie. The project is the company’s effort to advance psychedelics, including LSD, as a means of pain treatment.

The company is currently exploring two primary clinical indications for the treatment of pain. First, MindMed will initiate a study of LSD in a severe pain indication. It is in the process of preparing for a proof of concept study which it intends to submit to the US FDA in the second half of 2021.

MindMed is also evaluating a second indication in a common, often debilitating, chronic pain syndrome.

Silver47 Exploration Inc. — sponsored Sponsored · Silver47 Exploration Inc.

According to IQVIA, the global market for analgesics is expected to grow over US$31 billion by 2030. MindMed CEO J.R. Rahn relayed that Project Angie is related to the company’s mission to improve mental health and combat substance use. “If we can help to develop a new paradigm to treat pain, it may have the potential to greatly reduce the use of addictive medicines such as opioids currently ravaging society and its mental health,” said Rahn.

Earlier this year, MindMed also launched a clinical trial to combine LSD and MDMA, and began the study on LSD neutralizer technology that aims to stop the substance’s trip effects during therapy.

Mind Medicine Inc. last traded at US$3.38 on the Nasdaq.


Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Mind Medicine Boasts Current Cash Position Of US$161 Million

Mind Medicine (NEO: MMED) this morning released its fiscal year 2020 financial results. Given that...

Tuesday, March 30, 2021, 08:19:57 AM

Mind Medicine Pays JR Rahn $6.7 Million In Shares To Leave Leadership Roles

It seems that after selling $24.7 million in company stock, JR Rahn is looking to...

Wednesday, June 9, 2021, 07:50:06 AM

20-Year-Old Makes $110 Million From Bed Bath & Beyond Stock.. Next Stop: MindMed

20-year-old Jake Freeman just walked away with around $110 million from selling his 6.21% stake...

Thursday, August 18, 2022, 09:26:36 AM

Activist Investor Calls For MindMed CEO’s Termination Due To Alleged Fraudulent Acts

FCM MM Holdings, one of Mind Medicine’s (NEO: MMED) shareholders with a 6.1% stake, has...

Thursday, November 3, 2022, 03:10:00 PM

Champignon Brands Vs Mind Medicine: A Comparison

Champignon Brands (CSE: SHRM), prior to the public listing of the company, had a primary...

Monday, April 20, 2020, 09:01:13 AM